Equities

Neogenomics Inc

Neogenomics Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)14.23
  • Today's Change0.38 / 2.74%
  • Shares traded113.49k
  • 1 Year change-1.18%
  • Beta1.1197
Data delayed at least 15 minutes, as of Apr 26 2024 16:11 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.

  • Revenue in USD (TTM)591.64m
  • Net income in USD-87.97m
  • Incorporated1998
  • Employees2.10k
  • Location
    Neogenomics Inc9490 Neogenomics WayFORT MYERS 33912United StatesUSA
  • Phone+1 (239) 768-0600
  • Fax+1 (775) 329-0852
  • Websitehttps://neogenomics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Alignment Healthcare Inc1.82bn-148.02m975.12m1.54k--6.21--0.5347-0.7944-0.79449.790.83062.98--39.261,187,259.00-24.18---40.57--11.02---8.13-----5.880.5059--27.16--1.02------
Brookdale Senior Living, Inc.3.02bn-189.01m1.30bn25.20k--3.208.050.4307-0.8392-0.839213.392.140.524--57.91119,675.80-3.29-2.20-3.68-2.4824.7621.71-6.27-4.40--0.12130.9048--6.74-7.8220.73---12.60--
National HealthCare Corporation1.14bn66.80m1.40bn13.12k20.941.5313.021.224.344.3474.2359.200.882898.4310.9586,988.045.055.126.026.2137.6039.845.726.281.86--0.000949.355.143.09197.612.03-1.293.43
Addus Homecare Corporation1.06bn62.52m1.49bn6.06k23.912.1119.421.413.843.8464.9643.551.08--8.79174,723.706.375.187.426.0432.2430.885.914.96--9.640.14940.0011.3115.4335.8330.8312.06--
US Physical Therapy Inc604.80m18.14m1.51bn3.90k74.903.1628.582.501.341.3442.6431.770.6519--8.74155,117.204.017.135.6310.6420.0921.966.159.71--16.620.183658.539.345.91-38.011.785.2613.33
Veracyte Inc361.05m-74.40m1.53bn815.00--1.37--4.23-1.02-1.024.9714.250.31797.428.56443,007.40-6.55-6.33-6.93-6.6968.7367.10-20.61-20.994.40--0.0001--21.7631.45-103.51--39.67--
NeoGenomics, Inc.591.64m-87.97m1.77bn2.10k--1.87--2.99-0.7015-0.70154.717.390.345914.334.68281,734.80-5.14-3.57-5.44-3.8041.3441.09-14.87-9.365.95--0.3637--16.0716.4139.02--14.98--
Brightspring Health Services Inc8.83bn-154.60m1.78bn35.00k--2.1039.170.2019-0.9204-0.920457.534.96------252,176.40--------16.2417.75-1.78-0.62890.84420.97830.8473--14.3228.33-186.80--17.24--
Astrana Health Inc1.39bn60.72m2.05bn1.80k28.252.7927.091.481.291.2929.5613.111.46--11.07770,367.806.097.096.739.3915.5018.304.176.36----0.405510.5421.1921.6834.4241.1689.42--
Agilon Health Inc4.32bn-195.05m2.11bn1.12k--3.15--0.4885-0.4885-0.657610.511.632.51--5.993,864,246.00-11.36---20.26--7.13---4.52-----13,643.820.0551--80.74---112.01------
Privia Health Group Inc1.66bn23.08m2.13bn1.10k97.133.7977.451.290.18520.185213.304.751.85--6.901,504,299.002.35--3.91--9.749.151.27-2.56----0.00--22.1920.31368.83---12.48--
Teladoc Health Inc2.62bn-233.03m2.26bn5.60k--0.98617.080.8617-1.40-1.4015.8013.520.60719.5812.18467,732.50-5.40-33.54-5.93-34.6370.8168.59-8.90-171.393.74--0.4021--8.1344.1698.39--79.43--
Lifestance Health Group Inc1.06bn-186.26m2.35bn9.33k--1.63--2.22-0.5059-0.50592.873.770.4929--9.33113,208.00-8.70---9.54-------17.64-----5.690.1654--22.82--13.59------
Data as of Apr 26 2024. Currency figures normalised to Neogenomics Inc's reporting currency: US Dollar USD

Institutional shareholders

58.79%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Dec 202318.58m14.56%
The Vanguard Group, Inc.as of 31 Dec 202313.93m10.92%
Brown Advisory LLCas of 31 Dec 20239.64m7.56%
T. Rowe Price Investment Management, Inc.as of 31 Dec 20236.38m5.00%
Janus Henderson Investors US LLCas of 31 Dec 20236.28m4.92%
SSgA Funds Management, Inc.as of 31 Dec 20234.84m3.80%
Greenhouse Funds LLLPas of 31 Dec 20234.33m3.40%
Macquarie Investment Management Business Trustas of 31 Dec 20234.08m3.20%
First Light Asset Management LLCas of 31 Dec 20233.93m3.08%
Dimensional Fund Advisors LPas of 31 Dec 20233.01m2.36%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.